Compare Gigacloud Technology Inc (GCT) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Gigacloud Technology Inc trades at $57.53 (market cap $2.04B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 2.4× Gigacloud Technology Inc's market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 20 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| GCT | TVTX | |
|---|---|---|
Market Cap | $2.04B | $4.88B |
Volume | 633,969 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $57.75 | $67.52 |
52-Week Low | $25.46 | $26.79 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | $2.16B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GCT trades at $57.03, down 1.23% today, with a bullish technical outlook from moving averages but bearish oscillators. The company demonstrates strong fundamentals with consistent earnings beats, 10.65% net margins, and robust 32.34% ROE. Recent news highlights institutional interest and analyst optimism despite insider selling activity. Revenue growth continues with 2026 projections showing $1.5B revenue and maintained profitability.
GCT presents a compelling investment case with attractive valuation multiples (P/E 13.58) and strong execution, though technical indicators show overbought conditions. Key risks include market volatility and competitive pressures, but analyst consensus remains bullish with 66.7% buy ratings and $32.50 price target suggesting significant upside potential from current levels.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
